BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS announced two poster presentations featuring their GLIX1 compound at the 31st Society for Neuro-Oncology Annual Meeting & Education Day, scheduled for November 12-15 in Philadelphia, Pennsylvania.

Both presentations are set for November 13, 2026, from 7:30 to 9:30 p.m. EST at the Pennsylvania Convention Center.

The first presentation, titled "GLIX1, a TET2 activator targeting DNA damage response: potent anti-tumor activity across multiple glioblastoma models; orthotopic CDX models and a subcutaneous TMZ-resistant PDX model," will be delivered by Dr. Adam Robertson, Chief Scientific Officer of Hemispherian AS. It covers preclinical research evaluating GLIX1 across multiple glioblastoma models.

The second presentation, titled "Phase 1/2a study of GLIX1, a novel first-in-class oral TET2 activator, for the treatment of recurrent or progressive high-grade glioma," will be delivered by Ditte Primdahl, MD, of Northwestern University Feinberg School of Medicine. It covers the design of an ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or progressive high-grade glioma and other solid tumors.

GLIX1 is described as a small molecule targeting DNA damage response, being developed under a collaboration between BioLineRx and Hemispherian AS. The Phase 1/2a clinical trial was initiated in the first quarter of 2026, according to the companies' statement.